Green Alpha Advisors LLC Buys 251,271 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Green Alpha Advisors LLC grew its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 138.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 432,325 shares of the company's stock after buying an additional 251,271 shares during the period. Green Alpha Advisors LLC owned 0.46% of Caribou Biosciences worth $395,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CRBU. Centric Wealth Management bought a new position in Caribou Biosciences in the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. boosted its holdings in Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after buying an additional 21,416 shares during the period. MetLife Investment Management LLC boosted its holdings in Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after buying an additional 9,148 shares during the period. Diametric Capital LP bought a new position in Caribou Biosciences in the 4th quarter worth approximately $42,000. Finally, US Bancorp DE boosted its holdings in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after buying an additional 26,467 shares during the period. Hedge funds and other institutional investors own 77.51% of the company's stock.

Caribou Biosciences Price Performance

NASDAQ:CRBU traded down $0.02 during trading hours on Thursday, hitting $1.11. The stock had a trading volume of 301,550 shares, compared to its average volume of 1,410,336. The company has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $1.31. Caribou Biosciences, Inc. has a one year low of $0.66 and a one year high of $3.00. The firm has a market capitalization of $103.15 million, a price-to-earnings ratio of -0.67 and a beta of 2.44.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.